Navigation Links
FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes
Date:10/29/2008

m regular human insulin by its rapid onset and shorter duration of action. When used as a mealtime insulin, Apidra(R) should be given within 15 minutes before or within 20 minutes after starting a meal. Due to the short duration of action of Apidra(R), patients also require a longer-acting insulin or insulin infusion pump therapy. Any change of insulin should be made cautiously and only under medical supervision. Tell your doctor about all other medicines and supplements you are taking. Glucose monitoring is recommended for all patients with diabetes.

Possible side effects may include low blood sugar; injection site reactions, such as changes in fat tissue at the injection site; and allergic reactions, such as itching and rash. Less common, but potentially more serious or life-threatening, is generalized allergy to insulin, including anaphylactic reactions.

When used in a pump, do not mix Apidra(R) with any other insulin or liquid. If the pump or infusion set does not work right, you may not receive the right amount of insulin. Hypoglycemia, hyperglycemia, or ketosis can happen. Problems should be identified and corrected as quickly as possible.

For full prescribing information, please visit http://www.Apidra.com.

IMPORTANT SAFETY INFORMATION FOR LANTUS(R)

Prescription Lantus(R) is for adults with type 2 diabetes or adults and children (6 years and older) with type 1 diabetes who require long-acting insulin for the control of high blood sugar.

DO NOT DILUTE OR MIX LANTUS(R) WITH ANY OTHER INSULIN OR SOLUTION. It will not work as intended, and you may lose blood sugar control, which could be serious. Do not change your insulin without talking with your doctor. The syringe must not contain any other medication or residue. You should not use Lantus(R) if you are allergic to insulin. Lantus(R) is a long-acting insulin you inject just once a day, at the same time each day. You mus
'/>"/>

SOURCE Sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... BD (Becton, Dickinson and Company) (NYSE: ... today announced the acquisition of CRISI Medical Systems, a ... dedicated to improving the safety and delivery of IV ... address preventable medication errors and improve care delivery efficiencies. ... partnership in June 2013 to jointly develop the BD ...
(Date:3/2/2015)... N.Y. , March 2, 2015   Polymedco is ... for CRC.   During CRC Awareness Month, we are offering ... March. , Posters – to be ... , CRC Patient Brochures with Stand – to ... Reminder Post-its – to be put on/in patient charts ...
(Date:3/2/2015)... ANA, Calif. , March 2, 2015 /PRNewswire/ ... premier supplier of child-resistant packaging solutions for the ... Nicholas Kovacevich , has been nominated for ... The Excellence in Entrepreneurship Award is designed ... spirit – individuals who, by their creativity and ...
Breaking Medicine Technology:BD Acquires CRISI Medical Systems 2BD Acquires CRISI Medical Systems 3Polymedco CDP, LLC. Promotes March as Colorectal Cancer Awareness Month 2Kush Bottles CEO, Nicholas Kovacevich, Nominated for 2015 "Excellence in Entrepreneurship Award" 2
... Md., Feb. 11, 2011 The U.S. Food and ... test to help manage potential organ rejection in kidney ... the blood level of everolimus, a drug that helps ...   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) Everolimus, marketed under ...
... DIEGO, Feb. 11, 2011 Conatus Pharmaceuticals Inc. today ... Preferred Stock private placement financing.  This financing was led ... and included participation by existing investors; Aberdare Ventures, Advent ... Roche Venture Fund.  Conatus will use the proceeds to ...
Cached Medicine Technology:FDA Clears Test to Help Patients With Kidney Transplants 2Conatus Pharmaceuticals Completes $20 Million Series B Private Placement Financing 2
(Date:3/2/2015)... Getting customers to discover a whole ... this March as the 31st annual Frozen Food Month ... Frozen & Refrigerated Foods Association (NFRA) to stimulate the ... than 20 delicious frozen selections and is thrilled to ... frozen options are crafted with simple ingredients, no preservatives ...
(Date:3/2/2015)... York, New York (PRWEB) March 02, 2015 ... behalf of women who were allegedly harmed by the ... state and federal courts around the U.S., according to ... U.S. District Court, Eastern District of California on February ... a case pending in that jurisdiction may pursue her ...
(Date:3/2/2015)... Integrative Medicine a leader in bringing innovative naturopathic therapies ... bring about self-renewal. A 30 day detox is a ... house. According to Dr. Cutler, expert in environmental ... toxins like heavy metals, people’s food now becoming the ... we all have a level of toxic burden. ...
(Date:3/2/2015)... Monroeville, PA (PRWEB) March 02, 2015 ... part of the Allegheny Health Network, are ... with new software called Visual Info Zonal Reminder (VIZR), ... , Introduced in 2013, Google Glass is a wearable ... in a smartphone-like hands-free format. Wearers communicate with the ...
(Date:3/2/2015)... March 02, 2015 GBCHealth, a ... catalyzing private sector activities and investments in global ... elected four new members to serve on the ... Paul Farmer, Chief Strategist and Co-founder of Partners ... University; Dr. Huma Abbasi, General Manager of Global ...
Breaking Medicine News(10 mins):Health News:Take a Fresh Look at Frozen with Ian’s 2Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Court’s Decision to Allow Certain Claims to Stand in Mirena Injury Case 2Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Court’s Decision to Allow Certain Claims to Stand in Mirena Injury Case 3Health News:Mirena Lawsuit News: Bernstein Liebhard LLP Comments on Court’s Decision to Allow Certain Claims to Stand in Mirena Injury Case 4Health News:Skin and Wellness Power Couple give Quick Tips to Self-Renewal for Spring 2Health News:Pennsylvania Hospital Explores Use of Google Glass for Trauma Care 2Health News:Pennsylvania Hospital Explores Use of Google Glass for Trauma Care 3Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 2Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 3Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 4Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 5
... brought together a group of Philadelphia -area parents of children with juvenile diabetes on May 21, 1970 , she could never have ... ... , , ... ...
... Open defecation – the riskiest sanitation practice – is on the decline worldwide , ... , , ... ... GENEVA and NEW YORK , March ...
... 15 March 2010 Some of the most controversial ... the five-day 25th Annual Congress of the European Association of ... (ES). From April 16 to 20, close to 12,000 participants ... of the world,s biggest annual professional meetings in urology. ...
... study published in the March issue of Mayo ... a link between mild to moderate hypoglycemia (low blood ... multicenter study involved six medical centers from Australia, New ... to understand the epidemiology, severity, duration, recovery and outcome ...
... ... , ... (Vocus) March 15, 2010 -- Metagenics, Inc. announced today that it is ... the needs of menopausal women. The key active ingredient in Estrovera is ERr 731®, ...
... STOCKHOLM , March 15, 2010 Karolinska ... , , Key events during the year:, ... increased by 8.3 % to 6.9 (6.4) MSEK., - Operating ... amounted to -19.4 (-246.4) MSEK., - Income per share before ...
Cached Medicine News:Health News:JDRF Founder, Lee Ducat, To Be Honored at 40th Anniversary Gala in Philadelphia 2Health News:JDRF Founder, Lee Ducat, To Be Honored at 40th Anniversary Gala in Philadelphia 3Health News:JDRF Founder, Lee Ducat, To Be Honored at 40th Anniversary Gala in Philadelphia 4Health News:JDRF Founder, Lee Ducat, To Be Honored at 40th Anniversary Gala in Philadelphia 5Health News:JDRF Founder, Lee Ducat, To Be Honored at 40th Anniversary Gala in Philadelphia 6Health News:JDRF Founder, Lee Ducat, To Be Honored at 40th Anniversary Gala in Philadelphia 7Health News:JDRF Founder, Lee Ducat, To Be Honored at 40th Anniversary Gala in Philadelphia 8Health News:JDRF Founder, Lee Ducat, To Be Honored at 40th Anniversary Gala in Philadelphia 9Health News:Progress In Access To Safe Drinking-Water; Sanitation Needs Greater Efforts 2Health News:Progress In Access To Safe Drinking-Water; Sanitation Needs Greater Efforts 3Health News:Progress In Access To Safe Drinking-Water; Sanitation Needs Greater Efforts 4Health News:Progress In Access To Safe Drinking-Water; Sanitation Needs Greater Efforts 5Health News:Progress In Access To Safe Drinking-Water; Sanitation Needs Greater Efforts 6Health News:Progress In Access To Safe Drinking-Water; Sanitation Needs Greater Efforts 7Health News:Controversial urological issues top EAU's Anniversary Congress in Barcelona 2Health News:Metagenics Launches Estrovera™, an All-Natural, Clinically Demonstrated Alternative to Hormone Therapy for Relief of Hot Flashes and Other Menopausal Symptoms* 2Health News:Metagenics Launches Estrovera™, an All-Natural, Clinically Demonstrated Alternative to Hormone Therapy for Relief of Hot Flashes and Other Menopausal Symptoms* 3Health News:Metagenics Launches Estrovera™, an All-Natural, Clinically Demonstrated Alternative to Hormone Therapy for Relief of Hot Flashes and Other Menopausal Symptoms* 4Health News:Karolinska Development AB Announces Publication of Year End Report for 2009 2Health News:Karolinska Development AB Announces Publication of Year End Report for 2009 3
... Our ELISA products for autoimmune testing ... ELISAs, as well as specific reflex tests ... Sm, Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 ... family includes a full line of products ...
Anti-Skin Antibody (ASA) Test Kit: Pemphigus and Bullous Pemphigoid...
... and designs, the Digital ClearField lens ... the mid and far peripheral retina. ... image quality previously unattainable with the ... more detailed and comprehensive views, helping ...
... Peel PRESTIGE system was designed with advanced ... of the most demanding skin care practice. ... the Parisian Peel PRESTIGE machine is designed ... to offer maximum versatility and full abrasion ...
Medicine Products: